Rationale and design of the balANZ trial: A randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Johnson, David W ^a,b,f   Clarke, Margaret ^c,f   Wilson, Vanessa ^c,f   Woods, Feidhlim ^d,f   Brown, Fiona G ^e,f  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Australia Pty Ltd   (Australia)

^d Fresenius Medical Care Asia Pacific   (Hong Kong)

^e MONASH MEDICAL CENTRE   (Australia)

^f BalANZ Trial Study Group   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE DEGRADATION PRODUCT; PERITONEAL DIALYSIS FLUID; UREA; DIALYSIS FLUID;

ADULT; AMBULATORY PERITONEAL DIALYSIS; ANURIA; ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIALYSATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PH; PROSPECTIVE PAYMENT; RANDOMIZED CONTROLLED TRIAL; SOLUTE; SURVIVAL; ULTRAFILTRATION; URIC ACID URINE LEVEL; URINE VOLUME; ADOLESCENT; AGED; CHEMISTRY; KIDNEY; KIDNEY DISEASE; METHODOLOGY; MIDDLE AGED; PATIENT SELECTION; PHYSIOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIALYSIS SOLUTIONS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; PATIENT SELECTION; PERITONEAL DIALYSIS; RESEARCH DESIGN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957739076     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-25     Document Type: Article

References (33)

1. Continuous ambulatory peritoneal dialysis. RP Popovich JW Moncrief KD Nolph AJ Ghods ZJ Twardowski WK Pyle, Ann Intern Med 1978 88 449 456 637423
2. -30 years of peritoneal dialysis development: the past and the future. RT Krediet, Perit Dial Int 2007 27 Suppl 2 35 S41 17556326
3. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. KD Serkes CR Blagg KD Nolph EF Vonesh F Shapiro, Perit Dial Int 1990 10 15 19 2085575
4. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. EF Vonesh J Moran, J Am Soc Nephrol 1999 10 354 365 10215336
5. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates [see comments]. SS Fenton DE Schaubel M Desmeules HI Morrison Y Mao P Copleston JR Jeffery CM Kjellstrand, Am J Kidney Dis 1997 30 334 342 10.1016/S0272-6386(97)90276-6 9292560
6. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. MM Tanna EF Vonesh SM Korbet, Am J Kidney Dis 2000 36 1175 1182 10.1053/ajkd.2000.19832 11096042
7. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? EF Vonesh JJ Snyder RN Foley AJ Collins, Kidney Int Suppl 2006 3 11 10.1038/sj.ki.5001910 17080109
8. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. SJ Davies L Phillips PF Naish GI Russell, J Am Soc Nephrol 2001 12 1046 1051 11316864
9. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. N Topley, Adv Ren Replace Ther 1998 5 179 184 9686628
10. Beyond the membrane - the role of new PD solutions in enhancing global biocompatibility. R Pecoits-Filho P Stenvinkel O Heimburger B Lindholm, Kidney Int Suppl 2003 124 S132 10.1046/j.1523-1755.2003.08814.x 14870886
11. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. J Witowski A Jorres, Perit Dial Int 2005 25 Suppl 3 31 S34 16048252
12. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. N Topley, Perit Dial Int 1997 17 42 47 9068021
13. Effect of different buffers on the biocompatibility of CAPD solutions. HT Schambye, Perit Dial Int 1996 16 Suppl 1 130 S136 8728179
14. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]. B Nau CP Schmitt M Almeida K Arbeiter G Ardissino KE Bonzel A Edefonti M Fischbach K Haluany J Misselwitz, BMC Nephrol 2004 5 14 10.1186/1471-2369-5-14 15485574
15. Morphologic changes in the peritoneal membrane of patients with renal disease. JD Williams KJ Craig N Topley C Von Ruhland M Fallon GR Newman RK Mackenzie GT Williams, J Am Soc Nephrol 2002 13 470 479 11805177
16. Long-term effects of peritoneal dialysis on peritoneal morphology. JW Dobbie JD Anderson C Hind, Perit Dial Int 1994 14 Suppl 3 16 S20 7948267
17. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. S Mortier D Faict CG Schalkwijk NH Lameire AS De Vriese, Kidney Int 2004 66 1257 1265 10.1111/j.1523-1755.2004.00879.x 15327425 (Pubitemid 39121036)
18. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. S Mortier D Faict NH Lameire AS De Vriese, Kidney Int 2005 67 1559 1565 10.1111/j.1523-1755.2005. 00237.x 15780112
19. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. M Nakayama Y Kawaguchi K Yamada T Hasegawa K Takazoe N Katoh H Hayakawa N Osaka H Yamamoto A Ogawa, Kidney Int 1997 51 182 186 10.1038/ki.1997.22 8995732
20. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. K Honda K Nitta S Horita W Yumura H Nihei R Nagai K Ikeda S Horiuchi, Nephrol Dial Transplant 1999 14 1541 1549 10.1093/ndt/14.6.1541 10383022
21. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. B Rippe O Simonsen O Heimburger A Christensson B Haraldsson G Stelin L Weiss FD Nielsen S Bro M Friedberg, Kidney Int 2001 59 348 357 10.1046/j.1523-1755.2001.00497.x 11135090
22. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. JD Williams N Topley KJ Craig RK Mackenzie M Pischetsrieder C Lage J Passlick-Deetjen, Kidney Int 2004 66 408 418 10.1111/j.1523-1755.2004.00747.x 15200450
23. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). HY Lee HC Park BJ Seo JY Do SR Yun HY Song YH Kim YL Kim DJ Kim YS Kim, Perit Dial Int 2005 25 248 255 15981773
24. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. HY Lee HY Choi HC Park BJ Seo JY Do SR Yun HY Song YH Kim YL Kim DJ Kim, Nephrol Dial Transplant 2006 21 2893 2899 10.1093/ndt/gfl393 16957012
25. Impact of peritoneal dialysis solutions on outcomes. DW Johnson JD Williams, Evidence-based nephrology Oxford, UK: Blackwell, Molony DA, Craig JC, 2009
26. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. F Termorshuizen JC Korevaar FW Dekker JG Van Manen EW Boeschoten RT Krediet, Am J Kidney Dis 2003 41 1293 1302 10.1016/S0272-6386(03)00362-7 12776283
27. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. JM Bargman KE Thorpe DN Churchill, J Am Soc Nephrol 2001 12 2158 2162 11562415
28. Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. M Rumpsfeld SP McDonald DW Johnson, Perit Dial Int 2009 29 637 646 19910565
29. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. SL Fan T Pile S Punzalan MJ Raftery MM Yaqoob, Kidney Int 2008 73 200 206 10.1038/sj.ki.5002574 17914351
30. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products - a 1-year randomized control trial. CC Szeto KM Chow CW Lam CB Leung BC Kwan KY Chung MC Law PK Li, Nephrol Dial Transplant 2007 22 552 559 10.1093/ndt/gfl559 17005526
31. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. S Kim J Oh S Kim W Chung C Ahn SG Kim KH Oh, Nephrol Dial Transplant 2009 24 2899 2908 10.1093/ndt/gfp054 19258384
32. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. RW van Olden RT Krediet DG Struijk L Arisz, J Am Soc Nephrol 1996 7 745 750 8738810
33. Biocompatible dialysis fluids for peritoneal dialysis. KJ Wiggins GF Strippoli JC Craig DW Johnson, Cochrane Database Syst Rev 2009 D007554